It’s not about ‘new medicine,’ it’s about a ‘multibillion-dollar’ industry
By Kevin Sabet, Real Clear Wire
The Food and Drug Administration (FDA) appears closer than ever to approving psychedelic drugs like psilocybin and MDMA for medical use. But as political momentum builds in Washington and in the states, the evidence supporting these drugs deserves more scrutiny, not less.
Earlier this month, the Food and Drug Administration released its first finalized guidance on psychedelic drug development, explaining how these drugs should be studied for potential medical approval. The document marks a turning point. After decades of resistance, the FDA is signaling that psilocybin and MDMA are now on a path toward approval.
This seismic shift in psychedelics acceptance isn’t just about approving a new medicine. It’s about whether the federal government is laying the foundation for a multibillion-dollar commercial psychedelic industry before it has answered the fundamental scientific questions that should come first.